GlobeNewswire·Jun 2, 2026, 4:01 PM ET

NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

NRx Pharmaceuticals, Inc. intends to conduct an underwritten public offering of its common stock.
The company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares sold.
BTIG, LLC is acting as the lead bookrunner, with Lucid Capital Markets, LLC serving as the joint bookrunning manager.
Net proceeds from the offering are intended for working capital & general corporate purposes to support growth.
The offering is subject to market conditions & other factors, with no assurance regarding completion, size, or terms.
Shares will be offered pursuant to an effective shelf registration statement on Form S-3 filed with the SEC on December 22, 2025.
NRx Pharmaceuticals is developing therapeutics based on its NMDA platform for suicidal depression, chronic pain, & PTSD.
NRX-100 has received Fast Track Designation for suicidal ideation in depression & an ANDA has been filed.
NRX-101 has received Breakthrough Therapy Designation for suicidal bipolar depression.